This is a good stock to trade - lots of up and down. Lately on a downswing as their launch numbers for their 1st month were not up to expectations. It's all about the potential market size with this company. At 60K per patient per year, it won't take that many patients for them to amass big numbers, but there is great disagreement over the "treatment failure gout" population.